Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

57 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and immunogenicity of booster vaccination and fractional dosing with Ad26.COV2.S or BNT162b2 in Ad26.COV2.S-vaccinated participants.
Riou C, Bhiman JN, Ganga Y, Sawry S, Ayres F, Baguma R, Balla SR, Benede N, Bernstein M, Besethi AS, Cele S, Crowther C, Dhar M, Geyer S, Gill K, Grifoni A, Hermanus T, Kaldine H, Keeton RS, Kgagudi P, Khan K, Lazarus E, Le Roux J, Lustig G, Madzivhandila M, Magugu SFJ, Makhado Z, Manamela NP, Mkhize Q, Mosala P, Motlou TP, Mutavhatsindi H, Mzindle NB, Nana A, Nesamari R, Ngomti A, Nkayi AA, Nkosi TP, Omondi MA, Panchia R, Patel F, Sette A, Singh U, van Graan S, Venter EM, Walters A, Moyo-Gwete T, Richardson SI, Garrett N, Rees H, Bekker LG, Gray G, Burgers WA, Sigal A, Moore PL, Fairlie L. Riou C, et al. Among authors: ayres f. PLOS Glob Public Health. 2024 Apr 11;4(4):e0002703. doi: 10.1371/journal.pgph.0002703. eCollection 2024. PLOS Glob Public Health. 2024. PMID: 38603677 Free PMC article.
Homologous Ad26.COV2.S vaccination results in reduced boosting of humoral responses in hybrid immunity, but elicits antibodies of similar magnitude regardless of prior infection.
Moyo-Gwete T, Richardson SI, Keeton R, Hermanus T, Spencer H, Manamela NP, Ayres F, Makhado Z, Motlou T, Tincho MB, Benede N, Ngomti A, Baguma R, Chauke MV, Mennen M, Adriaanse M, Skelem S, Goga A, Garrett N, Bekker LG, Gray G, Ntusi NAB, Riou C, Burgers WA, Moore PL. Moyo-Gwete T, et al. Among authors: ayres f. medRxiv [Preprint]. 2023 Mar 15:2023.03.15.23287288. doi: 10.1101/2023.03.15.23287288. medRxiv. 2023. PMID: 36993404 Free PMC article. Updated. Preprint.
Homologous Ad26.COV2.S vaccination results in reduced boosting of humoral responses in hybrid immunity, but elicits antibodies of similar magnitude regardless of prior infection.
Moyo-Gwete T, Richardson SI, Keeton R, Hermanus T, Spencer H, Manamela NP, Ayres F, Makhado Z, Motlou T, Tincho MB, Benede N, Ngomti A, Baguma R, Chauke MV, Mennen M, Adriaanse M, Skelem S, Goga A, Garrett N, Bekker LG, Gray G, Ntusi NAB, Riou C, Burgers WA, Moore PL. Moyo-Gwete T, et al. Among authors: ayres f. PLoS Pathog. 2023 Nov 9;19(11):e1011772. doi: 10.1371/journal.ppat.1011772. eCollection 2023 Nov. PLoS Pathog. 2023. PMID: 37943890 Free PMC article.
Safety and immunogenicity of booster vaccination and fractional dosing with Ad26.COV2.S or BNT162b2 in Ad26.COV2.S-vaccinated participants.
Riou C, Bhiman JN, Ganga Y, Sawry S, Ayres F, Baguma R, Balla SR, Benede N, Bernstein M, Besethi AS, Cele S, Crowther C, Dhar M, Geyer S, Gill K, Grifoni A, Hermanus T, Kaldine H, Keeton RS, Kgagudi P, Khan K, Lazarus E, Roux JL, Lustig G, Madzivhandila M, Magugu SF, Makhado Z, Manamela NP, Mkhize Q, Mosala P, Motlou TP, Mutavhatsindi H, Mzindle NB, Nana A, Nesamari R, Ngomti A, Nkayi AA, Nkosi TP, Omondi MA, Panchia R, Patel F, Sette A, Singh U, van Graan S, Venter EM, Walters A, Moyo-Gwete T, Richardson SI, Garrett N, Rees H, Bekker LG, Gray G, Burgers WA, Sigal A, Moore PL, Fairlie L. Riou C, et al. Among authors: ayres f. medRxiv [Preprint]. 2023 Nov 20:2023.11.20.23298785. doi: 10.1101/2023.11.20.23298785. medRxiv. 2023. PMID: 38045321 Free PMC article. Updated. Preprint.
SARS-CoV-2 Beta and Delta variants trigger Fc effector function with increased cross-reactivity.
Richardson SI, Manamela NP, Motsoeneng BM, Kaldine H, Ayres F, Makhado Z, Mennen M, Skelem S, Williams N, Sullivan NJ, Misasi J, Gray GG, Bekker LG, Ueckermann V, Rossouw TM, Boswell MT, Ntusi NAB, Burgers WA, Moore PL. Richardson SI, et al. Among authors: ayres f. Cell Rep Med. 2022 Jan 17;3(2):100510. doi: 10.1016/j.xcrm.2022.100510. eCollection 2022 Feb 15. Cell Rep Med. 2022. PMID: 35233544 Free PMC article.
Ad26.COV2.S breakthrough infections induce high titers of neutralizing antibodies against Omicron and other SARS-CoV-2 variants of concern.
Kitchin D, Richardson SI, van der Mescht MA, Motlou T, Mzindle N, Moyo-Gwete T, Makhado Z, Ayres F, Manamela NP, Spencer H, Lambson B, Oosthuysen B, Kaldine H, du Pisanie M, Mennen M, Skelem S, Williams N, Ntusi NAB, Burgers WA, Gray GG, Bekker LG, Boswell MT, Rossouw TM, Ueckermann V, Moore PL. Kitchin D, et al. Among authors: ayres f. Cell Rep Med. 2022 Feb 10;3(3):100535. doi: 10.1016/j.xcrm.2022.100535. eCollection 2022 Mar 15. Cell Rep Med. 2022. PMID: 35474744 Free PMC article.
Enhanced neutralization potency of an identical HIV neutralizing antibody expressed as different isotypes is achieved through genetically distinct mechanisms.
Moyo-Gwete T, Scheepers C, Makhado Z, Kgagudi P, Mzindle NB, Ziki R, Madzorera S, Manamela NP, Ayres F, Lambson BE, Richardson SI, Morris L, Moore PL. Moyo-Gwete T, et al. Among authors: ayres f. Sci Rep. 2022 Oct 1;12(1):16473. doi: 10.1038/s41598-022-20141-7. Sci Rep. 2022. PMID: 36182959 Free PMC article.
Despite delayed kinetics, people living with HIV achieve equivalent antibody function after SARS-CoV-2 infection or vaccination.
Motsoeneng BM, Manamela NP, Kaldine H, Kgagudi P, Hermanus T, Ayres F, Makhado Z, Moyo-Gwete T, van der Mescht MA, Abdullah F, Boswell MT, Ueckermann V, Rossouw TM, Madhi SA, Moore PL, Richardson SI. Motsoeneng BM, et al. Among authors: ayres f. Front Immunol. 2023 Aug 3;14:1231276. doi: 10.3389/fimmu.2023.1231276. eCollection 2023. Front Immunol. 2023. PMID: 37600825 Free PMC article.
Comparing the immune abnormalities in MIS-C to healthy children and those with inflammatory disease reveals distinct inflammatory cytokine production and a monofunctional T cell response.
Butters C, Benede N, Moyo-Gwete T, Richardson SI, Rohlwink U, Shey M, Ayres F, Manamela NP, Makhado Z, Balla SR, Madzivhandila M, Ngomti A, Baguma R, Facey-Thomas H, Spracklen TF, Day J, van der Ross H, Riou C, Burgers WA, Scott C, Zühlke L, Moore PL, Keeton RS, Webb K. Butters C, et al. Among authors: ayres f. Clin Immunol. 2024 Feb;259:109877. doi: 10.1016/j.clim.2023.109877. Epub 2023 Dec 22. Clin Immunol. 2024. PMID: 38141746 Free article.
57 results